CG
TEVA icon

Cutler Group’s Teva Pharmaceuticals TEVA Stock Holding History

Cutler Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,900
Closed -$19K – 3566
2023
Q4 		$19K Hold
1,900
– – ﹤0.01% 2016
2023
Q3 		$19K Buy
+1,900
New +$17.7K ﹤0.01% 2080
2023
Q1 		– Sell
-16,395
Closed -$149K – 4702
2022
Q4 		$149K Sell
16,395
-14,472
-47% -$126K 0.01% 950
2022
Q3 		$249K Sell
30,867
-6,806
-18% -$60.2K 0.02% 852
2022
Q2 		$283K Buy
37,673
+5,016
+15% +$43.7K 0.02% 805
2022
Q1 		$306K Buy
32,657
+27,957
+595% +$233K 0.02% 926
2021
Q4 		$37K Buy
+4,700
New +$42.4K ﹤0.01% 2634
2021
Q1 		– Sell
-14,900
Closed -$143K – 6273
2020
Q4 		$143K Sell
14,900
-3,728
-20% -$35.7K 0.01% 1290
2020
Q3 		$167K Hold
18,628
– – 0.01% 1018
2020
Q2 		$229K Sell
18,628
-4,800
-20% -$54.3K 0.02% 807
2020
Q1 		$210K Buy
23,428
+7,712
+49% +$79K 0.01% 919
2019
Q4 		$154K Buy
15,716
+5,900
+60% +$52.7K 0.01% 968
2019
Q3 		$67K Sell
9,816
-4,434
-31% -$34K 0.01% 1335
2019
Q2 		$131K Buy
14,250
+14,116
+10,534% +$170K 0.01% 950
2019
Q1 		$2K Sell
134
-3,100
-96% -$54.7K ﹤0.01% 3465
2018
Q4 		$49K Hold
3,234
– – ﹤0.01% 1484
2018
Q3 		$69K Buy
3,234
+600
+23% +$13.9K ﹤0.01% 1413
2018
Q2 		$64K Sell
2,634
-3,366
-56% -$68.6K 0.01% 1450
2018
Q1 		$102K Buy
6,000
+4,566
+318% +$89.2K 0.01% 1170
2017
Q4 		$27K Sell
1,434
-37,474
-96% -$564K ﹤0.01% 2320
2017
Q3 		$684K Sell
38,908
-56,989
-59% -$1.28M 0.03% 503
2017
Q2 		$3.19M Sell
95,897
-48,986
-34% -$1.52M 0.12% 149
2017
Q1 		$4.65M Buy
144,883
+107,779
+290% +$3.68M 0.19% 98
2016
Q4 		$1.34M Buy
37,104
+21,518
+138% +$859K 0.05% 313
2016
Q3 		$717K Buy
15,586
+13,574
+675% +$708K 0.03% 448
2016
Q2 		$101K Buy
2,012
+1,551
+336% +$82.6K 0.01% 1689
2016
Q1 		$24K Buy
461
+161
+54% +$9.45K ﹤0.01% 3105
2015
Q4 		$19K Buy
+300
New +$18.5K ﹤0.01% 3475

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Cutler Group's TEVA Position: Q1 2024 in Review

Cutler Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2024, closing a stake of 1,900 shares — an estimated $19K sold.

Cutler Group first reported a position in TEVA in Q4 2015 and held it in 28 quarters. The position peaked at $4.65M in Q1 2017. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Cutler Group reported no remaining Teva Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 1,900 Teva Pharmaceuticals shares in Q1 2024, an estimated $19K.
  • Cutler Group first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 28 quarters.
  • Cutler Group's Teva Pharmaceuticals position peaked at $4.65M in Q1 2017.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.